PA8525801A1 - Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2 - Google Patents

Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2

Info

Publication number
PA8525801A1
PA8525801A1 PA20018525801A PA8525801A PA8525801A1 PA 8525801 A1 PA8525801 A1 PA 8525801A1 PA 20018525801 A PA20018525801 A PA 20018525801A PA 8525801 A PA8525801 A PA 8525801A PA 8525801 A1 PA8525801 A1 PA 8525801A1
Authority
PA
Panama
Prior art keywords
erab
hadh2
activity
modulate
inhibit
Prior art date
Application number
PA20018525801A
Other languages
English (en)
Inventor
Melwyn Abreo
Jerry J Meng
Charles Scott Agree
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of PA8525801A1 publication Critical patent/PA8525801A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

SE DESCRIBEN LOS COMPUESTOS PIRAZOL REPRESENTADOS POR LA FÓRMULA: (I) LOS COMPUESTOS PIRAZOL PUEDEN SER UTILIZADOS EN LA INHIBICIÓN DE LA ACTIVIDAD DE ERAB/HADH2 Y/O EN EL TRATAMIENTO DE LAS ENFERMEDADES Y AFECCIONES MEDIADAS POR ERAB/HADH2.
PA20018525801A 2000-08-18 2001-08-17 Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2 PA8525801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22612300P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
PA8525801A1 true PA8525801A1 (es) 2002-08-29

Family

ID=22847647

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018525801A PA8525801A1 (es) 2000-08-18 2001-08-17 Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2

Country Status (14)

Country Link
US (2) US20020132319A1 (es)
EP (2) EP1311511A1 (es)
JP (2) JP2004506737A (es)
AR (1) AR035486A1 (es)
AU (1) AU2001296854A1 (es)
BR (1) BR0113461A (es)
CA (2) CA2415182A1 (es)
GT (1) GT200100169A (es)
HK (1) HK1046288A1 (es)
MX (1) MXPA03001455A (es)
PA (1) PA8525801A1 (es)
PE (1) PE20020394A1 (es)
UY (1) UY26895A1 (es)
WO (1) WO2002016365A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
WO2004102151A2 (en) * 2003-05-06 2004-11-25 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties
WO2005041895A2 (en) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
WO2005117538A2 (en) 2004-04-12 2005-12-15 The Trustees Of Columbia University In The City Of New York METHODS AND COMPOSITIONS FOR INHIBITING ABAD/Aβ PROTEIN INTERACTION
US7888346B2 (en) * 2004-09-24 2011-02-15 Universtiy of Maryland, Baltimore Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
WO2023146880A1 (en) * 2022-01-25 2023-08-03 Board Of Regents Of The University Of Nebraska Functionalized allopurinol derivatives for treatment of alzheimer's disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3165520A (en) 1965-01-12 Certificate of correction
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
US5294611A (en) 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5556778A (en) * 1994-04-28 1996-09-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Crystalline Inha Enzyme-NADH Complex
PL181895B1 (pl) 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6153652A (en) 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6268479B1 (en) * 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
BR9808845A (pt) 1997-03-14 2000-08-01 Otsuka Pharma Co Ltd Derivado de pirimidina, agentes para a cura de uma doença alérgica, da asma e de uma dermatite atópica, agentes para inibição da produção de no de tnf-alfa, de citoquinas e da 5-lipoxigenase, processos para curar uma doença alérgica, a asma e uma dermatite atópica e para inibir a produção de no, de tnf-alfa e de citoquinas e a 5-lipoxigenase e usos de um composto
WO1998049166A1 (en) 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US5872011A (en) * 1997-06-13 1999-02-16 The Rockefeller University Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
US6020162A (en) * 1997-06-13 2000-02-01 The Rockefeller University Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
JP2002508324A (ja) * 1997-12-13 2002-03-19 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼ阻害剤としてのピラゾロ［３，４−ｂ］ピリジンの使用
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
GB9822238D0 (en) 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
AUPP672198A0 (en) 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
CA2370316A1 (en) 1999-06-10 2000-12-21 Warner-Lambert Company Rhodanine derivatives and their use in inhibiting and imaging amyloids
KR20020012266A (ko) 1999-06-10 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 이소인돌린 유도체를 사용한 아밀로이드 단백질 응집억제 방법 및 아밀로이드 침착물 영상화 방법
AU5311800A (en) 1999-06-10 2001-01-02 Warner-Lambert Company Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits
CA2382095A1 (en) 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof

Also Published As

Publication number Publication date
US20020132319A1 (en) 2002-09-19
GT200100169A (es) 2002-05-16
US20020065292A1 (en) 2002-05-30
EP1223176A2 (en) 2002-07-17
AR035486A1 (es) 2004-06-02
EP1311511A1 (en) 2003-05-21
BR0113461A (pt) 2003-07-01
UY26895A1 (es) 2002-04-26
PE20020394A1 (es) 2002-06-21
WO2002016365A1 (en) 2002-02-28
CA2354653A1 (en) 2002-02-18
US6964957B2 (en) 2005-11-15
EP1223176A3 (en) 2002-10-23
JP2004506737A (ja) 2004-03-04
AU2001296854A1 (en) 2002-03-04
JP2002360269A (ja) 2002-12-17
MXPA03001455A (es) 2004-05-04
CA2415182A1 (en) 2002-02-28
HK1046288A1 (zh) 2003-01-03

Similar Documents

Publication Publication Date Title
ES2181614T3 (es) Sulfonilfenilheterociclos sustituidos como inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
ECSP066312A (es) Derivados piridilo y su uso como agentes terapéuticos
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
EA200101166A1 (ru) Ингибиторы металлопротеаз
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
UY28510A1 (es) Compuestos quimicos
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
BR0312232A (pt) Inibidores de caspases e seus usos
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
ES2130152T3 (es) Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
UY28048A1 (es) Inhibidores de hiv-integrasa,composiciones farmacéuticas y métodos para su uso
ATE324112T1 (de) Topische behandlung bei der mastalgie
DE60026491D1 (de) Melagatran zur behandlung von entzündungen